Upper Tract Urothelial Carcinoma
Conditions
Interventions
experimental group:Patients received 3 cycles (Q3W) of induction therapy with EV 1.25 mg/kg (D1, D8) plus Toripalimab 240 mg (D1), followed by endoscopic laser ablation/coagulation of the tumor. After
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age >=18 years and =50%, tumor 2 years; 7. Signed informed consent and agreement to receive treatment and follow-up according to the plan.
Exclusion criteria
Exclusion criteria: 1. Imaging-confirmed >=cT3 stage, or N+, or distant metastasis; 2. Prior systemic anti-tumor therapy or radiotherapy for UTUC; 3. Severe anatomical alterations of the urinary tract or ureteral stricture preventing endoscopic intervention; 4. Contraindications to anesthesia, surgery, or medication, including intolerance to Enfortumab or Toripalimab; 5. Active infection (e.g., HBV, HCV, HIV, tuberculosis) or immunosuppressed state; 6. Autoimmune disease requiring systemic immunosuppressive therapy within the past 2 years; 7. Major cardiovascular or cerebrovascular disease, or severe medical comorbidities compromising safety; 8. Pregnant or lactating women; 9. Active malignancy other than UTUC within the past 5 years (except for skin basal /squamous cell carcinoma, carcinoma in situ of the cervix, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Conversion-Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease free survival;Metastasis free survival;Progression free survival;Renal function retention rate;Clinical complete remission rate; | — |
Countries
China
Contacts
Public ContactBao Yige
West China Hospital of Sichuan University
Outcome results
None listed